Impact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children

Ree Nar Yoo,1 Seo Hee Kim,1 and Jina Lee1,2

1Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; 2Division of Pediatric Infectious Diseases, University of Ulsan College of Medicine, Seoul, Korea

Received: 9 May 2016 Accepted: 11 September 2016

Address for Correspondence:
Jina Lee, MD
Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
E-mail: enter@amc.seoul.kr

Funding: This work was supported by a grant from Asan Institute for Life Sciences (Grant No. 2014-0300).

INTRODUCTION

Vancomycin is a glycopeptide antimicrobial with an important therapeutic role in treating invasive methicillin-resistant Staphylococcus aureus (MRSA) infection in children in community-associated (CA) and healthcare-associated (HA) settings (1). Because of the significant burden of MRSA infection in hospitals and the community, it is important to use vancomycin appropriately to ensure optimal drug exposure. Though some authors question the usefulness of therapeutic drug monitoring (TDM) of vancomycin and warn of unnecessary hospital costs, appropriate TDM is acknowledged as the most powerful method of adjusting vancomycin use in MRSA bacteremia (2). Studies of the pharmacokinetics and pharmacodynamics (PK/PD) of vancomycin have advocated that a ratio of the area under the curve to the minimum inhibitory concentration (AUC/MIC) of ≥ 400 is optimal for achieving clinical effectiveness in adults (3). This is frequently complemented by a recommended serum vancomycin C\textsubscript{\text{t\text{r}ough}} of > 15 μg/mL when the MIC is 1 μg/mL; to avoid the emergence of resistance, it should at least be maintained above 10 μg/mL (4). However, these recommendations are mainly based on guidelines supported by adult data and may not extrapolate to young children.

Despite extensive use of vancomycin in children, information about the optimal regimen to achieve PK/PD targets in the pediatric population remains limited (5). Recent PK/PD studies suggest that routine aggressive dosing may be unnecessary in pediatric invasive MRSA infections, because a C\textsubscript{\text{t\text{r}ough}} of 7–10 μg/mL at a dose of 15 mg/kg every 6 hours predicted achievement of AUC/MIC > 400 in > 90% of children infected by MRSA with MIC ≤ 1 μg/mL (6). In addition, the relationship between the C\textsubscript{\text{t\text{r}ough}} and AUC in neonates is similar to those in children regardless of gestational age and kidney function (7). Therefore, higher trough concentrations of 15 to 20 μg/mL are likely to be unnecessary in children and neonates based on AUC/MIC considerations (6,7). Meanwhile vancomycin treatment failure in
MRSA bacteremia is most common in premature infants and immunocompromised individuals, even though vancomycin trough serum concentrations ≥ 15 µg/mL are achieved (8).

The aims of this study were to determine whether initial C_{trough} could be used as a practical parameter for predicting clinical and microbiological outcomes with the cut-off value at 10 µg/mL, which is the minimum level avoiding the emergence of heteroresistant vancomycin-intermediate S. aureus (4), and anticipating achievement of AUC/MIC > 400 in pediatric MRSA infection by pharmacokinetic modeling (6,7).

**MATERIALS AND METHODS**

**Study populations**

This retrospective study was conducted at Asan Medical Center Children’s Hospital, which is a 252 bed university-affiliated tertiary hospital located in Seoul, Korea; it has a pediatric intensive care unit (PICU), neonatal intensive care unit (NICU), hematology/ oncology ward, surgical ward, and general pediatric wards.

Children aged under 18 years with culture-confirmed MRSA bacteremia, who were hospitalized in our institute during the study period from January 2010 to April 2014, were eligible for enrollment. Other focal infections without bloodstream infection were not included. Patients were included only if they received vancomycin for at least 48 hours and their initial C_{trough} had been checked within ≤ 96 hours of start of treatment. Corresponding clinical data including demographic profiles, diagnoses, primary sites of infection, underlying diseases, durations of hospital stay, intensive care unit (ICU) stays, need for mechanical ventilation, and HA risk factors were abstracted retrospectively from electronic medical records. Only the first MRSA isolate detected during a single clinical episode occurring within a 4-week period was included in the analysis, and duplicates from the same patient were excluded. Patients were included regardless of their underlying medical conditions such as congenital heart diseases, genetic/metabolic diseases, hemato-oncological diseases, chronic lung diseases, and neurological disorders. However, patients on renal replacement therapy such as hemodialysis, or neonates admitted to the nursery or NICU were excluded.

Initial dosages of vancomycin (mg/kg/day), which was determined by the reference of ‘Pediatric and Neonatal Dosage Handbook’ (9), and the resulting serum vancomycin concentration data were collected. The first trough sample before the 4th or 5th dose was obtained within 30 minutes prior to the next dose of vancomycin.

**Definitions**

Fever was defined as any temperature ≥ 38.0°C. The primary focus of infection was defined as the culture-positive site and/or a clinically evident site of infection concomitant with bacteremia, and central line-associated blood stream infection (CLABSI) was defined according to the Centers for Disease Control and Prevention (CDC) guidelines (10). Recurrent MRSA bacteremia was defined as MRSA regrowth on blood cultures after at least one culture-negative month (11). Co-infection was defined as the isolation of an organism in addition to MRSA from the same initial blood culture, or clinical or laboratory evidence of viral infection at the time of isolation of MRSA.

**Strain identification and antimicrobial susceptibility testing**

Isolates were identified and the antimicrobial susceptibilities of the S. aureus isolates were decided using a MicroScan WalkAway 96-Combo Pos 28 panels (Siemens, West Sacramento, CA, USA). This machine contained six vancomycin wells with concentrations ranging from 0.5 to 16.0 µg/mL and the maximum MIC value within the range was selected to determine MIC_{50} and MIC_{90}. Antimicrobial susceptibility testing data included 8 antibiotics; gentamicin, ciprofloxacin, trimethoprim/ sulfamethoxazole, rifampin, tetracyclin, clindamycin, linezolid, and vancomycin. MRSA isolate of intermediate resistance or full resistance were defined as resistant. The in vitro macrolide-lincosamide-streptogramin B (MLS_{B})-inducible phenotype was detected by the D-zone test (double-disk diffusion test). Multi-drug-resistance (MDR) was defined as acquired non-susceptibility to at least one agent in each of three or more antimicrobial categories (12).

**Clinical/microbiological outcomes**

To evaluate the clinical and microbiological outcomes according to C_{trough} level, the children with MRSA bacteremia were divided into those with initial vancomycin C_{trough} < 10 µg/mL and ≥10 µg/mL, respectively. As measures of clinical outcome we included resolution of fever after 48 hours of vancomycin use, recurrent MRSA bacteremia, and 30-day all-cause fatality. To evaluate microbiological outcomes, we compared time to negative conversion of blood culture and presence of persistent bacteremia at 48–72 hours of vancomycin administration.

**Statistical analysis**

While continuous variables were compared using the independent t-tests or analysis of variance (ANOVA), the χ² test or Fisher’s exact test were used for categorical variables. Risk factors for 30-day mortality or persistent bacteremia at 48 hours were investigated by logistic regression analysis. P values were 2-sided and considered significant at P < 0.05 using SPSS 18.0 (SPSS Inc., Chicago, IL, USA).

**Ethics statement**

This study was approved by the Institutional Review Board of
Asan Medical Center with a waiver of informed consent for retrospective, de-identified data collection and analysis (IRB No. 2014-0300).

RESULTS

Patient characteristics
During the study period from January 2010 to April 2014, a total of 61 cases of MRSA bacteremia occurred in our institute among individuals < 18 years old. Of these, 15 were excluded for the following reasons; 12 patients required hemodialysis or NICU stay, 2 in whom vancomycin C\textsubscript{trough} was not monitored, and one treated with teicoplanin. Finally, 46 episodes of MRSA bacteremia were included in the analysis and the demographic and clinical characteristics of the patients are shown in Table 1. Mean age of patients was 22.0 ± 46.9 months (range, 0–17 years old) and 82.6% (38 out of 46) were aged under 24 months; 54.3% (25 of 46) were male. All were HA MRSA cases and occurred in children with underlying medical conditions, the majority with congenital heart disease. Of the cases, 41.3% were primary MRSA bacteremia while the others involved definite focal infections including CLABSI (41.3%, 19/46), pneumonia (15.2%, 7/46), ventriculoperitoneal shunt infection (4.3%, 2/46) and surgical site infection (4.3%, 2/46); none of them were bone and joint infections or skin and soft tissue infections. Fever was the most frequent initial symptom (34/46, 73.9%) and 16 (34.8%) patients presented with unstable vital signs including hypotension, bradycardia and respiratory difficulty. However, non-specific find-

Table 1. Characteristics of children with MRSA bacteremia according to the initial vancomycin trough concentration (C\textsubscript{trough})

| Characteristics                      | C\textsubscript{trough} < 10 μg/mL (n = 35) | C\textsubscript{trough} ≥ 10 μg/mL (n = 11) | Total (n = 46) | P value* |
|---------------------------------------|-----------------------------------------------|-------------------------------------------|----------------|---------|
| Mean age ± SD, mon                    | 26.6 ± 52.9                                   | 7.3 ± 8.3                                  | 22.0 ± 46.9    | 0.045   |
| Sex of male, No. (%)                  | 19 (54.3)                                    | 6 (45.4)                                  | 25 (56.3)      | 0.988   |
| Hospital stay before onset of the MRSA bacteremia ± SD, day | 17.2 ± 37.9                                   | 106.5 ± 179.0                             | 38.5 ± 94.6    | 0.005   |
| Underlying disease                    |                                               |                                           |                |         |
| Congenital heart disease              | 15 (42.9)                                    | 6 (45.4)                                  | 21 (45.7)      | 0.497   |
| Congenital megacolon                  | 3 (8.6)                                      | 1 (8.1)                                   | 4 (8.7)        | 0.957   |
| Chronic lung disease                  | 2 (5.7)                                      | 1 (8.1)                                   | 3 (6.5)        | 0.315   |
| Cancer                                 | 3 (8.6)                                      | 0 (0.0)                                   | 3 (6.5)        | 0.315   |
| Neurologic diseases                   | 8 (22.9)                                     | 3 (23.9)                                  | 11 (23.9)      | 0.765   |
| Others†                               | 10 (28.6)                                    | 3 (23.9)                                  | 13 (28.9)      | 0.933   |
| Presence of co-infection†             | 1 (2.9)                                      | 2 (18.2)                                  | 3 (6.5)        | 0.138   |
| Presence of an invasive device†       | 26 (74.3)                                    | 11 (100.0)                                | 37 (80.4)      | 0.061   |
| Initial clinical symptom              |                                               |                                           |                |         |
| Presence of fever (≥ 38.0°C)          | 27 (77.1)                                    | 7 (63.6)                                  | 34 (73.9)      | 0.374   |
| Unstable vital signs†                 | 8 (22.9)                                     | 8 (22.9)                                  | 16 (34.8)      | 0.002   |
| ICU stay                              | 16/35 (45.7)                                 | 9/10 (90.0)                               | 25/45 (55.6)   | 0.013   |
| Need for mechanical ventilation       | 15/35 (42.9)                                 | 8/10 (80.0)                               | 23/45 (51.1)   | 0.038   |
| Initial laboratory finding            |                                               |                                           |                |         |
| WBC in peripheral blood, /μL         | 16.022 ± 9.492                               | 20.018 ± 12.241                          | 16.978 ± 10.488| 0.275   |
| Serum CRP, mg/dL                      | 7.5 ± 10.9                                   | 5.5 ± 5.7                                 | 7.0 ± 9.9      | 0.553   |
| Serum BUN, mg/dL                      | 12.1 ± 7.6                                   | 16.8 ± 5.5                                | 13.3 ± 7.4     | 0.080   |
| Serum creatinine, mg/dL               | 0.3 ± 0.1                                    | 0.4 ± 0.3                                 | 0.3 ± 0.2      | 0.073   |
| Primary focus of MRSA bacteremia      |                                               |                                           |                |         |
| None                                  | 13 (37.1)                                    | 6 (45.4)                                  | 19 (41.3)      | 0.307   |
| CLABSI                                | 15 (42.9)                                    | 4 (36.4)                                  | 19 (41.3)      | 0.703   |
| Pneumonia                             | 6 (17.1)                                     | 1 (8.1)                                   | 7 (15.2)       | 0.517   |
| Others‡                               | 4 (11.4)                                     | 0 (0.0)                                   | 4 (8.7)        | 0.241   |
| Removal of primary focus             | 6 (17.1)                                     | 1 (8.1)                                   | 7 (15.2)       | 0.517   |
| Simultaneous use of other antibiotics, No. (%) | 28 (80.0)                       | 9 (81.8)                                  | 39 (84.8)      | 0.895   |
| Mean ± SD of initial vancomycin dose, mg/kg/day | 41.0 ± 8.1                                   | 39.4 ± 7.6                                | 40.6 ± 7.9     | 0.536   |
| Mean ± SD of initial C\textsubscript{trough}, μg/mL | 5.6 ± 2.0                                    | 15.6 ± 5.8                                | 8.0 ± 5.4      | < 0.001 |

MRSA = methicillin-resistant \textit{Staphylococcus aureus}, SD = standard deviation, ICU = intensive care unit, WBC = white blood cell, CRP = C-reactive protein, BUN = blood urea nitrogen, CLABSI, central line-associated blood stream infection.

*In each indicated age group, continuous variables were compared using the independent t-test. Binominal variables were compared using the χ\textsuperscript{2} test; †Others includes surgical conditions such as congenital diaphragmatic hemia, congenital megacolon, hypospadias, jejunal atresia, tracheoesophageal fistula, omphalocele and other endocrine disease such as hypothyroidism, and pseudohypoaldoteronism; ‡Co-infections included respiratory viral infections such as rhinovirus (n = 2) and adenovirus (n = 1); §Invasive devices included vascular catheters (n = 26), tracheostomy (n = 3), gastrostomy (n = 3), ventriculoperitoneal shunt (n = 2), and colonostomy (n = 1); ¶Unstable vital signs means any of the signs of bradycardia, respiratory difficulty, and hypotension, or requirement of vasopressor; •Others includes ventriculo-peritoneal shunt infections (n = 2) and superficial surgical site infections (n = 2).
ings such as vomiting or nausea were observed as an initial symptom in 5 (10.9%) patients, and 1 (2.2%) patient had no clinical symptoms other than a finding of elevated C-reactive protein (CRP). Mean duration of fever to initial positive culture was 1.9 ± 2.4 days.

**Clinical manifestations according to vancomycin C_{trough}**

Initial average dose of vancomycin was 40.6 ± 7.9 mg/kg/day (range, 21.4–63.1 mg/kg/day). The initial C_{trough} was 8.0 ± 5.4 μg/mL (range, 2.3–25.6 μg/mL), and only 4 (8.7%) patients achieved the C_{trough} ≥ 15 μg/mL. Numbers (%) of children according to range of initial C_{trough} were as follows; C_{trough} < 5 μg/mL, 14 (30.4%), ≥ 5 μg/mL to < 10 μg/mL, 21 (45.7%), and ≥ 10 μg/mL to < 15 μg/mL, 7 (15.2%).

The patients belonging to the group with initial C_{trough} < 10 μg/mL were older (26.6 ± 52.9 months vs. 7.3 ± 8.3 months; P = 0.045), had a shorter hospital stay prior to MRSA bacteremia (17.2 ± 37.9 days vs. 106.5 ± 179.0 days; P = 0.005) and showed relatively milder clinical courses; initial presentation with unstable vital signs, ICU stay and requirement for mechanical ventilation were less frequent in the group with C_{trough} < 10 μg/mL (22.9% vs. 72.7%, P = 0.002; 45.7% vs. 90.0%, P = 0.013; 42.9% vs. 80.0%, P = 0.038, respectively) (Table 1). However, no significant differences were observed between the groups with initial vancomycin C_{trough} < 10 μg/mL and ≥ 10 μg/mL in the other aspects including presence of underlying disease, primary focus of infection and whether the primary focus was removed or not.

**Clinical and microbiological outcomes**

Clinical outcomes associated with MRSA bacteremia were analyzed in only 45 cases because one patient was transferred to a care hospital within 14 days from the onset of MRSA bacteremia (Table 2). Severe diseases requiring ICU stay, mechanical ventilation and/or resulting in death were observed in 57.8% (26/45); all-cause 30-day fatality was 11.1% (5/45) with average duration from onset of MRSA bacteremia to death of 11.8 days (range, 2–20 days). Nephrotoxicity defined as an increase in serum creatinine of 0.5 mg/dL from baseline occurred in one patient with initial C_{trough} of 6.6 μg/mL; none of the 4 children with high vancomycin troughs of > 15 μg/mL developed nephrotoxicity.

As follow-up blood culture at 48–72 hours was missed in some cases, 36 of the 46 cases could be included in the analysis of initial microbiological outcomes at 48–72 hours of vancomycin administration; persistent bacteremia at 48–72 hours was observed in 63.9% (23/36) of these patients (Table 2). Average time to negative conversion for the first time was 5.3 ± 4.5 days. MRSA bacteremia recurred in 7 (15.2%) patients after at least one culture-negative month; 3 were CLABSI and 4 had primary bacteremia without a definite focus. All of the recurrent CLABSI cases had a history of salvage therapy without removal of the infected central venous catheter. Mean recurrence interval was 80 days (range, 28–260 days).

**Impact of vancomycin C_{trough} on clinical and microbiological outcomes**

There was no statistically significant difference between the two groups with initial vancomycin C_{trough} < 10 μg/mL and ≥ 10 μg/mL, in terms of clinical outcome including 30-day mortality and recurrence (P = 0.899, and P = 0.754, respectively) (Table 2). However, persistent bacteremia at 48 hours was observed more frequently in the group with initial C_{trough} < 10 μg/mL (77.8%, compared to 33.3%; P = 0.032), and these patients had a tendency to require longer time for negative conversion (5.3 days, compared to 3.5 days; P = 0.236). Although univariate logistic regression analysis suggested initial C_{trough} < 10 μg/mL was associated with persistent bacteremia at 48 hours (odds ratio [OR], 7.00; 95% confidence interval [CI], 1.02–47.97), multivariate logistic regression analysis could not identify statistically significant predictors for persistent bacteremia at 48–72 hours and 30-

---

**Table 2. Clinical and microbiological outcomes of children with MRSA bacteremia according to initial vancomycin trough concentration (C_{trough}) and vancomycin MIC**

| Characteristics                     | C_{trough} < 10 (n = 35) | C_{trough} ≥ 10 (n = 11) | P value* | MIC < 1.0 (n = 12) | MIC = 1.0 (n = 27) | MIC > 1.0 (n = 7) | P value* |
|-------------------------------------|---------------------------|---------------------------|----------|-------------------|-------------------|-------------------|----------|
| **Microbiologic outcome†**          |                           |                           |          |                   |                   |                   |          |
| Time to negative conversion, day    | 5.3 ± 4.5                 | 3.5 ± 2.5                 | 0.236    | 6.1 ± 6.5         | 4.1 ± 2.8         | 5.7 ± 4.0         | 0.350    |
| Persistent bacteremia at 48 hr‡     | 21/27 (77.8)              | 2/6 (33.3)                | 0.032    | 6/9 (66.7)        | 12/19 (63.2)      | 5/5 (100.0)       | 0.273    |
| Persistent bacteremia at 72 hr §    | 18/31 (58.1)              | 2/5 (40.0)                | 0.451    | 5/9 (55.6)        | 10/21 (47.6)      | 5/6 (83.3)        | 0.300    |
| **Clinical outcome**                |                           |                           |          |                   |                   |                   |          |
| Recurrent MRSA infection†           | 5/35 (14.3)               | 2/11 (18.2)               | 0.754    | 3/12 (25.0)       | 2/27 (7.4)        | 2/7 (28.6)        | 0.209    |
| Resolution of fever at 48 hr§       | 11/27 (40.7)              | 3/7 (42.9)                | 0.919    | 7/11 (63.6)       | 9/18 (50.0)       | 4/5 (80.0)        | 0.447    |
| All-cause fatality within 30 day†    | 4/35 (11.4)               | 1/10 (10.0)               | 0.899    | 3/12 (25.0)       | 2/26 (7.7)        | 0/7 (0.0)         | 0.171    |

MRSA = methicillin-resistant Staphylococcus aureus; MIC = minimum inhibitory concentration.

*Continuous variables were compared by the independent t-tests or analysis of variance (ANOVA), and the χ² test or Fisher’s exact test were used for categorical variables; †Microbiological outcome analysis was done in the available cases because follow-up blood cultures within 72 hours were missed in some cases; ‡Recurrent MRSA infection was defined as MRSA regrowth after at least one month of culture-negativity; §Because some cases presented without fever at the onset of MRSA bacteremia, only febrile cases are included; †One patient, who was transferred to care hospital within 14 days from the onset of MRSA bacteremia, could not be included in this analysis.
### DISCUSSION

Our findings suggest that initial \( C_{\text{trough}} < 10 \mu g/mL \) could be used as a predictor of microbiological failure at 48 hours of vancomycin therapy for children with MRSA bacteremia, even though multivariate logistic regression analysis could not identify statistical significance. However, initial \( C_{\text{trough}} < 10 \mu g/mL \) did not significantly influence 30-day mortality or recurrence even when we adjusted for clinical status at presentation. This may be partly due to the better clinical outcomes in pediatric MRSA bacteremia than in adult cases. Indeed, overall 30-day mortality associated with MRSA bacteremia was 11.1% in this study, which was much lower than that in adult patients (13). A recent prospective cohort study reported a 25.6%, 30-day mortality of invasive MRSA infections in a Korean population with median age 64 years (14). It may be pointless to monitor initial vancomycin \( C_{\text{trough}} \) to optimize final clinical outcomes in pediatric MRSA bacteremia, in which, compared to adult cases, relatively favorable outcomes can be expected regardless of initial vancomycin \( C_{\text{trough}} \).

The AUC of vancomycin is a well-known theoretical PK/PD model reflecting the effectiveness of vancomycin exposure (15). Because it is nearly impossible to measure an accurate AUC in clinical practice especially in young children, it is important to develop an appropriate PK/PD model. In our study, more than 80% of our study population was less than 24 months old and no very appropriate model for calculating AUC was available in this age group; estimation of an AUC using vancomycin clearance and creatinine clearance based on the model developed by Frymoyer et al. (16), was originally developed to predict vancomycin AUC/MIC in children aged 2 to 12 years. Although a Bayesian model employing the serum creatinine value and one set of trough and peak vancomycin concentrations has been developed to estimate a PK model for vancomycin in young children (17,18), our study was conducted retrospectively and the standard of care in our institute involves checking only trough levels during vancomycin therapy.

There is controversy regarding the association of vancomycin MIC and clinical outcomes, in some reports higher vancomycin MIC value had a higher likelihood of treatment failure (19). There is no very appropriate model for calculating AUC in children not (20,21). In this study, vancomycin MIC did not impact on the clinical and microbiologic outcomes of MRSA bacteremia in young children.

This study had some limitations. First, it was retrospective and included a relatively small number of patients and about one-fourth of the cases of MRSA bacteremia could not be included in the initial microbiological outcome analysis because of missing follow-up blood cultures within 72 hours, even though it is recommended that follow-up blood cultures should be con-

### Table 3. Risk factors for persistent bacteremia and 30-day fatality in pediatric MRSA bacteremia

| Variables                        | Persistent bacteremia at 48 hours | 30-day all-cause fatality |
|----------------------------------|-----------------------------------|---------------------------|
|                                  | Unadjusted*                        | Adjusted*                 | Unadjusted* | Adjusted* |
| Mean age                         | 1.01 (0.99–1.03)                   | 1.00 (0.98–1.03)          | 1.01 (0.99–1.02) | 1.01 (0.99–1.01) |
| Hospital day before the onset of the MRSA bacteremia | 0.99 (0.98–1.00)                   | 1.00 (0.98–1.01)          | 1.00 (1.00–1.01) | 1.00 (0.99–1.01) |
| Presentation with unstable vital signs | 0.65 (0.13–3.47)                   | 2.00 (0.14–28.02)         | 3.50 (0.52–23.70) | 6.66 (0.39–95.24) |
| ICU stay                         | 0.73 (0.16–3.28)                   | 1.55 (0.06–39.70)         | 3.62 (0.37–35.29) | 1.76 (0.12–25.68) |
| Need for mechanical ventilation | 0.77 (0.17–3.41)                   | 1.29 (0.05–31.40)         | Not applicable¹ | Not applicable¹ |
| Initial \( C_{\text{trough}} \) | 0.91 (0.77–1.07)                   | 1.15 (0.83–1.58)          | 0.96 (0.78–1.18) | 0.98 (0.69–1.40) |
| Initial \( C_{\text{trough}} < 10 \mu g/mL \) | 7.00 (1.02–47.97)                  | 33.81 (0.22–5,174.94)     | 1.16 (0.11–11.74) | 2.68 (0.01–524.77) |

Values are presented as odds ratio (95% confidence interval).

MRSA = methicillin-resistant Staphylococcus aureus, ICU = intensive care unit.

*Univariate logistic regression analysis was carried out including the factors that were significantly different depending on initial \( C_{\text{trough}} \) as presented in Table 1; Multivariate logistic regression was done adjusting for the any risk factors included in the univariate analysis; "All of the fatal cases required mechanical ventilation.

Antimicrobial susceptibilities

Among the 46 MRSA isolates, the multi-drug resistance rate was 46.9% and 69.6% were resistant to erythromycin. With an erythromycin-inducible clindamycin resistance rate of 88.9% (8/9), the overall rate of resistance to clindamycin was 52.2% (24/46). Frequencies of resistance to trimethoprim/sulfamethoxazole and rifampin were 2.2% (1/46) and 4.3% (2/46), respectively. The vancomycin MIC\( _{\text{trough}} \) and MIC\( _{\text{peak}} \) were 1.0 and 2.0 \( \mu g/mL \), respectively. MRSA isolates with vancomycin MIC \(< 1.0 \mu g/mL\), 1.0 \( \mu g/mL \), and > 1.0 \( \mu g/mL \) comprised 26.1% (12/46), 58.7% (27/46), and 15.2% (7/46), respectively, and no MRSA isolates with vancomycin MIC \( > 2.0 \mu g/mL \) were detected.

The clinical and microbiological outcomes of the children with MRSA bacteremia according to the vancomycin MIC are shown in Table 2, however, vancomycin MIC did not significantly influence clinical and microbiologic outcomes of MRSA bacteremia in this study.
ducted every 48 to 72 hours until a negative result is obtained in our institute. Second, during the study period from January 2010 to April 2014, the initial dose of vancomycin was usually 40 mg/kg/day—with some exceptions such as central nervous system (CNS) infections where a starting dose of 60 mg/kg/day was used based on the Pediatric and Neonatal Dosage Handbook (9)—even though this is suboptimal according to the recent recommendation of a daily dose of 60 mg/kg in children. Since 2012–2013, however, the recommended initial dose of vancomycin was increased from 40 mg/kg/day to 60 mg/kg/day with further modification according to the TDM report in cases of invasive MRSA infection regardless of CNS or non CNS infection. Vancomycin is a well-known age-dependent pharmacokinetic antibiotic, because creatinine clearance has a crucial role in vancomycin pharmacodynamics and the vancomycin clearance of children is 2 or 3 times higher than that of adults (14,19). As a consequence, it was hard to obtain the adult target range in most children with the dosage of 40 mg/kg/day. Thirdly, the paucity of appropriate models for calculating AUCs given only the serum trough values of vancomycin in younger children under 2 years old made it difficult to determine whether the PK/PD parameters were comparable to the data obtained in older population groups. However, there have been few clinical studies to determine the impact of the vancomycin C_\text{trough} and MIC on clinical and microbiological outcomes in MRSA bacteremia among young children <2 years old, and the only available literature being theoretical PK/PD models predicting clinical outcomes in pediatric MRSA infections (6,22).

In conclusion, initial C_\text{trough} may be a useful TDM parameter in pediatric MRSA bacteremia for reducing early microbiological failure, though it did not impact on final clinical outcomes including 30-day fatality. Further prospective data on vancomycin dosing are needed to find the optimal drug exposure and clarify its impact on clinical outcomes in pediatric populations.

ACKNOWLEDGMENT

This manuscript was presented in part at the IDWeek 2014, in Philadelphia, Pennsylvania, USA, October 8–12, 2014.

DISCLOSURE

The authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Study concept and design: Lee J. Data acquisition: Yoo RN, Kim SH. Analysis and interpretation of the data: Yoo RN, Kim SH, Lee J. Writing and revision: Yoo RN, Lee J. Final approval of manuscript submission: all authors.

ORCID

Ree Nar Yoo http://orcid.org/0000-0003-1288-7158
Seo Hee Kim http://orcid.org/0000-0001-7564-7675
Jina Lee http://orcid.org/0000-0002-3435-251X

REFERENCES

1. Chen SY, Hsuheh PR, Chiang WC, Huang EP, Lin CE, Chang CH, Chen SC, Chen WI, Chang SC, Lai MS, et al. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteremia. J Infect 2014; 69: 259-65.
2. Suryadevara M, Steidl KE, Probst LA, Shaw J. Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costs. J Pediatr Pharmacol Ther 2012; 17: 159-65.
3. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-42.
4. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-92.
5. Le I, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, Cho S, Natale S, But I, Tran TM, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J 2013; 32: e155-63.
6. Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections. Pediatr Infect Dis J 2013; 32: 1077-9.
7. Frymoyer A, Hersh AL, El-Komy MH, Gaskari S, Su F, Drover DR, Van Meurs K. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. Antimicrob Agents Chemother 2014; 58: 6145-61.
8. Welsh KJ, Abbott AN, Lewis EM, Gardiner JM, Kruzel MC, Lewis CT, Mohr JJ, Wanger A, Armitige LY. Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin. J Clin Microbiol 2010; 48: 894-9.
9. Taketomo CK, Hodding JH, Kraus DM. Pediatric and Neonatal Dosage Handbook. 18th ed. Hudson, OH: Lexi-Comp, 2011.
10. Centers for Disease Control and Prevention (US). Bloodstream Infection Event (Central Line-associated Bloodstream Infection and Non-central Line-associated Bloodstream Infection). Atlanta, GA: Centers for Disease Control and Prevention, 2016, p4:1-32.
11. Sung IV, Lee J, Choi EH, Lee HJ. Changes in molecular epidemiology of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Korean children. Diagn Microbiol Infect Dis 2012; 74: 28-33.
resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.

13. Kim CJ, Kim HB, Oh MD, Kim Y, Kim A, Oh SH, Song KH, Kim E, Cho Y, Choi Y, et al. The burden of nosocomial *Staphylococcus aureus* bloodstream infection in South Korea: a prospective hospital-based nationwide study. BMC Infect Dis 2014; 14: 590.

14. Song KH, Kim ES, Sin HY, Park KH, Jung SI, Yoon N, Kim DM, Lee CS, Jang HC, Park Y, et al. Characteristics of invasive *Staphylococcus aureus* infections in three regions of Korea, 2009-2011: a multi-center cohort study. BMC Infect Dis 2013; 13: 581.

15. Patel K, Crumby AS, Maples HD. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC? Paediatr Drugs 2015; 17: 97-103.

16. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant *Staphylococcus aureus* infections is inadequate. Pediatr Infect Dis J 2009; 28: 398-402.

17. Le J, Ngu B, Bradley JS, Murray W, Nguyen A, Nguyen L, Romanowski GL, Vo T, Capparelli EV. Vancomycin monitoring in children using bayesian estimation. Ther Drug Monit 2014; 36: 510-8.

18. Hahn A, French RW Jr, Zou Y, Vinks AA. Validation of a pediatric population pharmacokinetic model for vancomycin. Ther Drug Monit 2015; 37: 413-6.

19. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in *Staphylococcus aureus* infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54: 755-71.

20. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC Jr, Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in *Staphylococcus aureus* infections. J Infect Dis 2009; 199: 532-6.

21. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, et al. Antibiotic choice may not explain poorer outcomes in patients with *Staphylococcus aureus* bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204: 340-7.

22. Stockmann C, Sherwin CM, Zobell JT, Lubsch I, Young DC, Olson J, Noyes BE, Ampeo K, Spigarelli MG. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis. Pharmacotherapy 2013; 33: 1288-96.